Cost‐effectiveness of office‐based, magnetic resonance imaging‐guided transperineal versus transrectal prostate biopsy: An economic analysis of the PREVENT trial
In this model, TP biopsy was more cost-effective than TR from a health care payer perspective. In the setting of increasing concerns about the risk of infection from traditional TR biopsy, these findings suggest that office-based TP biopsy is a more cost-effective population-level alternative.
Authors
- Brandon Malik Wahba (ORCID: https://orcid.org/0000-0002-8767-5195)
- Conor Driscoll (ORCID: https://orcid.org/0000-0001-7730-6145)
- Ali Jalali (ORCID: https://orcid.org/0000-0003-4349-1519)
- Hiten D. Patel (ORCID: https://orcid.org/0000-0003-4028-010X)
- Jim C. Hu (ORCID: https://orcid.org/0000-0003-3406-5542)
- Aaron A. Laviana (ORCID: https://orcid.org/0000-0001-9057-7580)
- Nicole Handa (ORCID: https://orcid.org/0000-0002-0700-7200)
- Mitchell M. Huang
- Edward M. Schaeffer
Institutions
- Northwestern University (US)
- Cornell University (US)
- Jesse Brown VA Medical Center (US)
- Weill Cornell Medicine (US)
- The University of Texas at Austin (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1002/cncr.70118
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Prostate Cancer Foundation
- National Cancer Institute